
WHAT IS CLAIMED IS:

1. Use of Compound 1:



1,

or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a solid tumor in a patient, wherein the compound is to be administered at an amount of from 5 mg to 500 mg, by weight of Compound 1 free base, once daily (QD) or twice daily (BID).

2. The use of claim 1, wherein the solid tumor is lung cancer.

3. The use of claim 2, wherein the lung cancer is an advanced or metastatic lung cancer.

4. The use of claim 3, wherein the compound is to be administered at an amount of from 25 mg to 100 mg, by weight of Compound 1 free base, per day.

5. The use of any one of claims 1 to 4, wherein the solid tumor is non-small cell lung cancer (NSCLC).

6. The use of any one of claims 1 to 5, wherein the solid tumor is an advanced solid tumor.

7. The use of claim 6, wherein the advanced solid tumor is relapsed after, refractory to, or resistant to the prior treatment by a tyrosine kinase inhibitor (TKI).

8. The use of any one of claims 1 to 7, wherein the solid tumor is metastatic.

9. The use of claim 8, wherein the solid tumor is CNS metastatic.

10. The use of any one of claims 1 to 9, wherein the solid tumor is ROS1 positive.

11. The use of any one of claims 1 to 10, wherein the solid tumor comprises a ROS1 mutation.

12. The use of claim 11, wherein the ROS1 mutation is one or more mutations selected from G2032R, S1986F, L1951R, L1982F, G2032K, F2004C, F2004V, L2026M, D2033N, and G2101A.

13. The use of any one of claims 1 to 12, wherein the solid tumor comprises a ROS1 fusion.

14. The use of any one of claims 1 to 13, wherein the solid tumor is ALK positive (e.g. ALK fusion) or LTK positive.

15. The use of any one of claims 1 to 14, wherein:

(a) the patient is naïve to tyrosine kinase inhibitor (TKI) therapy;

(b) the patient has been treated with one prior TKI therapy;

(c) the patient has been treated with at least one prior TKI therapy; or

(d) the patient has been treated with at least two prior TKI therapies;

optionally wherein the TKI is ROS1 TKI; or

optionally wherein the prior TKI therapy is one or more selected from the group consisting of crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, repotrectinib, cabozantinib, foretinib, merestinib, taletrectinib, masitinib, and ensartinib.

16. The use of any one of claims 1 to 15, wherein:

(a) the patient has not been treated with prior platinum-based chemotherapy;

(b) the patient has been treated with up to one prior platinum-based chemotherapy;

(c) the patient has been treated with one prior platinum-based chemotherapy;

(d) the patient has not been treated with immunotherapy;

(e) the patient has been treated with immunotherapy;

(f) the patient has not been treated with chemotherapy;

(g) the patient has been treated with at least one prior line of chemotherapy;

(h) the patient has been treated with at least two prior lines of chemotherapy;

(i) the patient has been treated with at least three prior lines of anticancer therapy; or

(j) the patient has been treated with at least two prior lines of anticancer therapy selected from the group consisting of ROS1 TKI (*e.g.*, investigational ROS1 TKI, crizotinib, lorlatinib, entrectinib, repotrectinib, and taletrectinib) and chemotherapy.

17. The use of any one of claims 1 to 16, wherein:

(a) the patient has been treated with at least one line of ROS1 TKI and one line of chemotherapy;

(b) the patient has been treated with at least two lines of ROS1 TKI and one line of chemotherapy;

(c) the patient has been treated with at least three lines of ROS1 TKI and one line of chemotherapy;

(d) the patient has been treated with at least two lines of chemotherapy;

(e) the patient has been treated with at least one line of ROS1 TKI and two lines of chemotherapy;

(f) the patient has been treated with at least two lines of ROS1 TKI and two lines of chemotherapy; or

(g) the patient has been treated with at least three lines of ROS1 TKI and two lines of chemotherapy;

optionally wherein the ROS1 TKI is crizotinib, entrectinib, lorlatinib, or repotrectinib; or

optionally wherein the patient has been treated with lorlatinib and repotrectinib.

18. The use of any one of claims 1 to 17, wherein the solid tumor is locally advanced or metastatic ROS1-positive solid tumor, and the patient has been treated with at least one prior ROS1 TKI therapy.

19. The use of any one of claims 1 and 2 to 17, wherein the solid tumor is locally advanced or metastatic ROS1-positive NSCLC, and the patient is naïve to TKI therapy and has been treated with up to one prior platinum-based chemotherapy with or without immunotherapy.

20. The use of any one of claims 1 and 2 to 17, wherein the solid tumor is locally advanced or metastatic ROS1-positive NSCLC, and the patient has been treated with one prior ROS1 TKI therapy and has not been treated with prior platinum-based chemotherapy or immunotherapy.

21. The use of any one of claims 1 and 2 to 17, wherein the solid tumor is locally advanced or metastatic ROS1-positive NSCLC, and the patient has been treated with one prior ROS1 TKI therapy and one prior platinum-based chemotherapy with or without immunotherapy.

22. The use of any one of claims 1 and 2 to 17, wherein the solid tumor is locally advanced or metastatic ROS1-positive NSCLC, and the patient has been treated with at least two prior ROS1 TKI therapies and up to one prior platinum-based chemotherapy with or without immunotherapy.

23. The use of any one of claims 1 to 17, wherein the solid tumor is locally advanced or metastatic ROS1-positive solid tumor, and the patient has progressed on a prior therapy,

24. The use of any one of claims 18 and 20-22, wherein the prior ROS1 TKI is crizotinib, lorlatinib, entrectinib, repotrectinib, or taletrectinib.

25. The use of any one of claims 1 to 24, wherein Compound 1 is to be administered to the patient for at least one treatment cycle, optionally wherein one treatment cycle is at least 7 days, at least 14 days, at least 21 days, or at least 28 days.

26. The use of any one of claims 1 to 25, wherein the compound is to be administered at an amount of from 50 mg to 100 mg, by weight of Compound 1 free base, per day.

27. The use of claim 26, wherein the compound is to be administered at an amount of 100 mg, by weight of Compound 1 free base, once daily (QD).

28. The use of claim 26, wherein the compound is to be administered at an amount of 75 mg, by weight of Compound 1 free base, once daily (QD).

29. The use of claim 26, wherein the compound is to be administered at an amount of 50 mg, by weight of Compound 1 free base, once daily (QD).

30. The use of any one of claims 1 to 29, wherein the compound is Compound 1 free base; and/or wherein the compound to be administered is a solid form of Compound 1 characterized by an XRPD pattern comprising peaks at 10.7, 15.0, and 21.2º 2θ ±0.2º.

31. The use of any one of claims 1 to 30, wherein the compound is to be administered as a pharmaceutical composition comprising Compound 1, or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, and a diluent, a binder, a disintegrant, and a lubricant,

optionally wherein the diluent is mannitol, the binder is a mixture of HPC and SMCC, the disintegrant is sodium starch glycolate (SSG), and the lubricant is magnesium stearate.